Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 5/2011

01-11-2011 | Gynecologic Oncology

Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival

Authors: Çiğdem Berna Ege, Metin Akbulut, Osman Zekioğlu, Necmettin Özdemir

Published in: Archives of Gynecology and Obstetrics | Issue 5/2011

Login to get access

Abstract

Introduction

Inhibitors of tumor angiogenesis and metastasis are emerging as important new drug candidates for cancer therapy. Galectin-3 and heparanase have been shown to function in tumor progression and metastatic spread. Both of them exert pleiotropic effects; proliferation, cell migration, differentiation and tissue remodeling. The aim of this study was to investigate heparanase and galectin-3 expression in endometrioid and serous carcinomas of the endometrium and their relation with well-known prognostic factors, in addition to estrogen, progesterone, C-erbB-2, Ki-67 and p53.

Materials and methods

Sixty-four endometrial cancers, which include 24 serous types, were obtained from previously untreated patients. Immunohistochemical analysis of 64 carcinomas, 20 endometrial hyperplasia (ten of simple hyperplasia and ten of complex atypic hyperplasia) and 20 normal endometrium (ten of proliferative and ten of secretory) was performed.

Conclusion

This investigation suggests that the decreased expression of galectin-3 may be involved in the pathogenesis of endometrial carcinomas from normal endometrium to carcinoma. Also down-regulated stromal expression of galectin-3 in endometrial carcinoma may be involved in lymph node metastasis. Further studies on a larger advanced stage (FIGO stage 3–4) endometrial carcinoma group may determine the value of heparanase in the endometrial carcinoma.
Literature
1.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al (2005) Cancer statistics 2005. CA Cancer J Clin 55:10–30PubMedCrossRef
2.
3.
Ronnett BM, Zaino RJ, Ellenson LH, Kurman JR (2002) Endometrial carcinoma. In: Kurman RJ (ed) Blaustein’s pathology of female genital tract, 5th edn. Springer Verlag, Berlin, pp 501–559
4.
International Federation of Gynecology and Obstetrics: Annual report on the results of treatment in gynecologic cancer: FIGO. Stockholm, Sweden, International Federation of Gynecology and Obstetrics, 1985
5.
Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, Raz A (1999) The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 59:6239–6245PubMed
6.
Califice S, Castronovo V, van den Brule F (2004) Galectin-3 and cancer. Int J Oncol 25:983–992PubMed
7.
Krzeslak A, Lipinska A (2004) Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9:305–328PubMed
8.
Dangue A, Camby I, Kiss R (2002) Galectins and cancer. Biochim Biophys Acta 1572:285–293
9.
Von Wolff M, Wang X, Gabius HJ, Strowitzki T (2005) Galectin-3 fingerprinting in human endometrium and decidua during the menstrual cycle and in early gestation. Mol Hum Reprod 11:189–194CrossRef
10.
Lehr JE, Pienta KJ (1998) Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90:118–123PubMedCrossRef
11.
Robert L, Jacob MP, Fülöp T, Timar J, Hornebeck W (1989) Elastonectin and the elastin receptor. Pathol Biol 37:736–741PubMed
12.
Inufusa H, Nakamura M, Adachi T, Aga M, Kurimoto M, Nakatani Y et al (2001) Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol 19:913–919PubMed
13.
Poirier F (2002) Roles of galectins in vivo. Biochem Soc Symp 69:95–103PubMed
14.
15.
16.
Nakajima M, Irimura T, Nicolson GL (1998) Heparanases and tumor metastasis. J Cell Biochem 36:1–11
17.
Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ihai-Michaeli R, Lider O et al (1992) Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12:112–127PubMed
18.
Kodama J, Shinyo Y, Hasengaowa, Kusumoto T, Seki N, Nakamura K, Hongo A, Hiramatsu Y (2005) Loss of basement membrane heparan sulfate expression is associated with pelvic lymph node metastasis in invasive cervical cancer. Oncol Rep 14(1):89–92
19.
Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW et al (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety, optimal dosage. J Hepatol 50(5):958–968PubMedCrossRef
20.
Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB (1999) Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 59:344–3433
21.
Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M et al (1994–1995) Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14:290–302
22.
Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C et al (2007) PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 33:557–568PubMedCrossRef
23.
Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT et al (2008) Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 68:72–77PubMedCrossRef
24.
Van den Brule FA, Waltregny D, Liu FT, Castronovo V (2000) Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89:361–367PubMedCrossRef
25.
Shimonishi T, Miyazaki K, Kono N, Sabit H, Tuneyama K, Harada K et al (2001) Expression of endogenous gal-1 and gal-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302–310PubMedCrossRef
26.
Sanjuan X, Fernandez PL, Castells A, Catronovo V, Van Den Brule F (1997) Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113:1906–1915PubMedCrossRef
27.
Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR (2000) Decreased galectin-3 expression in prostate cancer. Prostate 44:118–123PubMedCrossRef
28.
Idikio H (1998) Galectin-3 expression in human breast carcinoma: correlation with cancer histological grade. Int J Oncol 12:1287–1290PubMed
29.
Van den Brule FA, Califice S, Castronovo V (2004) Expression of galectins in cancer: a critical review. Glycoconj J 19:537–542PubMedCrossRef
30.
Brustmann H, Riss D, Naude S (2003) Galectin-3 expression in normal, hyperplastic, and neoplastic endometrial tissues. Pathol Res Pract 199:151–158PubMedCrossRef
31.
van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT et al (1996) Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Human Pathol 27:1185–1191CrossRef
32.
Lloyd RV (2001) Distinguishing benign from malignant thyroid lesions: galectin-3 as the latest candidate. Endocr Pathol 12:255–257PubMedCrossRef
33.
Weinberger PM, Adam BL, Gourin CG, Moretz WH, Bollag RJ, Wang BY et al (2007) Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 133:503–510PubMedCrossRef
34.
Carcangiu ML, Steeper T, Zampi G, Rosai J (1985) Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83:135–158PubMed
35.
Langbein S, Brade J, Badawi JK, Hatzinger M, Kaltner H (2007) Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance. Histopathology 51:681–690PubMedCrossRef
36.
Yoshimura A, Gemma A, Hosoya Y, Komaki E, Hosomi Y (2003) Increased expression of the LGALS3 (galectin3) gene in human non-small-cell lung cancer. Genes Chromosomes Cancer 37:159–164PubMedCrossRef
37.
Lapis K, Timar J (2002) Role of elastin-matrix interactions in tumor progression. Semin Cancer Biol 12:209–217PubMedCrossRef
38.
Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, Natoli C et al (2002) Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol 20:3850–3856PubMedCrossRef
39.
Plzak J, Betka J, Smetana KJ, Chovanec M, Kaltner H (2004) Galectin-3-an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer 40:2324–2330PubMedCrossRef
40.
Gaudin JC, Arar C, Monsigny M, Legrand A (1997) Modulation of the expression of the rabbit galectin-3 gene by p53 and c-Ha-ras proteins and PMA. Glycobiology 7:1089–1098PubMedCrossRef
41.
Ceehinelli B, Lavra L, Rinaldo C, Iacovelli S, Gurtner A, Gasbarri A et al (2006) Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 26:4746–4757CrossRef
42.
Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, Bresalier RS, Raz A (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 24:4395–4406PubMedCrossRef
43.
Kim HR, Lin HM, Bilirian H, Raz A (1999) Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast cells. Cancer Res 59:4148–4154PubMed
44.
Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci 93:6737–6742PubMedCrossRef
45.
Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HRC (2001) Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol 159:1055–1060PubMedCrossRef
46.
Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J (2006) Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168:1666–1675PubMedCrossRef
47.
van den Brule FA, Engel J, Stetler-Stevenson WG et al (1992) Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J Cancer 52:653–657PubMedCrossRef
48.
Le Marer N (2000) Galectin-3 expression in differentiating human myeloid cells. Cell Bio Int 24:245–251CrossRef
49.
Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A et al (2003) cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22:2680–2688PubMedCrossRef
50.
Petrov SV, Raskin GA, Khasanov RS (2006) A new hypothesis on the role of c-erbB2 oncogene in the progress of breast cancer. Bull Exp Biol Med 142:94–97PubMedCrossRef
51.
Yoshii T, Inohara T, Takenaka Y, Honjo Y, Akahani S, Nomura T, Raz A, Kubo T (2001) Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18:787–792PubMed
52.
Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I et al (2000) Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma: evidence for its role in colonic tumourigenesis. Am J Pathol 157:1167–1175PubMedCrossRef
53.
Ikuta M, Podyma KA, Maruyama K, Enomoto S, Yanagishita M (2001) Expression of heparanase in oral cancer cell lines and oral cancer tissues. Oral Oncol 37:177–184PubMedCrossRef
54.
Ueno Y, Yamamoto M, Vlodavsky I, Pecker I, Ohshima K, Fukushima T (2005) Decreased expression of heparanase in glioblastoma multiforme. J Neurosurg 102:513–521PubMedCrossRef
55.
Ikeguchi M, Hirooka Y, Kaibara N (2003) Heparanase gene expression and its correlation with spontaneous apoptosis in hepatocytes of cirrhotic liver carcinoma. Eur J Cancer 39:86–90PubMedCrossRef
56.
Stadlmann S, Moser PL, Pollheimer J, Steiner P, Krugman J, Dirnhofer S, Mikuz G, Margreiter R, Amberger A (2003) Heparanase-1 gene expression in normal, hyperplastic and neoplastic prostatic tissue. Eur J Cancer 39:2229–2233PubMedCrossRef
57.
Watanabe M, Aoki Y, Kase H, Tanaka K (2003) Heparanase expression and angiogenesis in endometrial cancer. Gynecol Obstet Invest 56:77–82PubMedCrossRef
58.
Inamine M, Nagai Y, Hirakawa M, Mekaru K, Yagi C, Masamoto H et al (2008) Heparanase expression in endometrial cancer: analysis of immunohistochemistry. J Obstet Gynaecol 28:634–637PubMedCrossRef
59.
Hasengaowa, Kodama J, Kusumoto T, Seki N, Matsuo T, Ojima Y et al (2006) Heparanase expression in both normal endometrium and endometrial cancer. Int J Gynecol Cancer 16(3):1401–1406
60.
Canaani J, Ilan N, Back S, Gutman G, Vlodavsky I, Grisaru D (2008) Heparanase expression increases throughout the endometrial hyperplasia-cancer sequence. Int J Gynaecol Obstet 101:166–171PubMedCrossRef
61.
Xu X, Rao G, Quiros RM, Kim AW, Miao HQ, Brunn GJ, Platt JL, Gattuso P, Prinz RA (2007) In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem 282:2363–2373PubMedCrossRef
62.
El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N (2001) The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7:1299–1305PubMed
Metadata
Title
Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival
Authors
Çiğdem Berna Ege
Metin Akbulut
Osman Zekioğlu
Necmettin Özdemir
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 5/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-010-1766-9

Other articles of this Issue 5/2011

Archives of Gynecology and Obstetrics 5/2011 Go to the issue

Materno-fetal Medicine

Microscopic lesions of placenta and Doppler velocimetry related to fetal growth restriction

Reproductive Medicine

Factor V Leiden G1691A and factor II G20210A point mutations and pregnancy in North-West of Iran

General Gynecology

Is methotrexate an acceptable treatment in the management of idiopathic granulomatous mastitis?

Materno-fetal Medicine

Pregnancy outcome in late maternal age in a high-income developing country

Gynecologic Oncology

Involvement of ARLTS1 in chemotherapy and apoptosis in ovarian cancer cell line

Materno-fetal Medicine

Macrosomia prediction using different maternal and fetal parameters in women with 50 g glucose challenge test between 130 and 140 mg/dl